All News

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy
February 25, 2021

Results of a phase 2 trial testing the efficacy of idecabtagene vicleucel in patients with heavily pretreated myeloma are reported.

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER
February 25, 2021

In the phase 3 CheckMate 9ER trial, investigators found that nivolumab plus cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously untreated advanced renal cell carcinoma.

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC
February 24, 2021

In the CheckMate 9ER trial, investigators compared combination treatment with nivolumab and cabozantinib versus sunitinib in patients with previously treated advanced renal cell carcinoma.